Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Research and Markets: Targacept's TC-5619 - The prospects for this fully-owned alpha-7 neuronal nicotinic receptor agonist

Research and Markets
Posted on: 07 Jan 13

Research and Markets (http://www.researchandmarkets.com/research/g8jxmm/targacepts) has announced the addition of the "Targacept's TC-5619 - The prospects for this fully-owned alpha-7 neuronal nicotinic receptor agonist" report to their offering.

In 2011, Targacept reported that its phase II proof of concept study of TC-5619 in cognitive dysfunction in schizophrenia (CDS) met the pre-specified primary endpoint, while the trial in ADHD missed the primary endpoint but showed signals of drug activity. However, AstraZeneca subsequently decided not to exercise its option to license TC-5619, and Targacept retains full rights to the compound. The company plans to continue its development with a new phase IIb trial but with a slight change in direction.

In this report, we review the scientific rationale, the early safety and activity data as a means to gauge TC-5619's prospects in what is a huge market opportunity with a significant unmet need.

Key Topics Covered:

INTRODUCTION AND BACKGROUND

1. Schizophrenia

- Epidemiology

- Clinical picture

- Diagnosis

- Disease mechanisms

- Current treatments focus on neurotransmitters

- Potential mechanisms and treatments under investigation

- Non-pharmacologic approaches to treatment

TC-5619 - an alpha-7 NNR agonist

1. Mechanism of action and rationale

2. Favorable evidence in animal models

3. Adequate preclinical safety

4. Phase I

5. Phase II proof-of-concept study in cognitive dysfunction in schizophrenia

- Activity

- Safety

6.TC-5619 in other indications

- Phase II in attention deficit/hyperactivity disorder

- Phase I in Alzheimer's Disease

REGULATORY BACKGROUND:

1. The MATRICS initiative:

- Inclusion criteria:

- Add-on Design:

- Duration:

- Outcome measures:

- Cognitive outcome:

- Functional outcome:

- Outcomes measures - International issues

OPINION

1. Concens about the choice of endpoints

2. Statistical concerns

3. Dosing concerns

4. Functional Outcomes - required in the setting of cognition

5. Secondary Endpoint - what do they show?

6. Differential Effect In Smokers Vs. Non-Smokers

7. Geographical Imbalances

8. Concomitant Medications

9. Safety And Adverse Events

10. Challenges For Phase III Trials

MARKET OPPORTUNITY AND COMPETITION

1. The market opportunity

2. Pipeline

- Neuronal nicotinic receptor agonists

- Drugs with other mechanisms of action

CONCLUSIONS

For more information visit http://www.researchandmarkets.com/research/g8jxmm/targacepts

Business Wire
http://www.businesswire.com/

Last updated on: 07/01/2013

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.